Canaccord Genuity Reiterates a Buy Rating on TSO3 Inc. J

By Ryan Adsit

The Healthcare company, TSO3 Inc. J (TSX: TOS), has received a rating update from a Wall Street analyst today. Analyst Neil Maruoka from Canaccord Genuity rated TSO3 Inc. J (TSX: TOS) a Buy, setting a C$5.25 price target.

According to TipRanks.com, Maruoka is a 1-star analyst with an average return of -2.3% and a 33.9% success rate. Maruoka covers the Healthcare sector, focusing on stocks such as Merus Labs International, Cardiome Pharma Corp, and Concordia Healthcare.

TSO3 Inc. J has an analyst consensus of Strong Buy, with a price target consensus of C$4.75.

The company has a one year high of C$3.82 and a one year low of C$2.11. Currently, TSO3 Inc. J has an average volume of 142.9K.

TSO3, Inc. engages in the business of medical devices. Its activities include manufacturing, sale; research and development, licensing of sterilization processes, related consumable supplies and accessories for heat-sensitive medical devices. The company was founded by Jocelyn Vézina and Simon Robitaille on June 10, 1998 and is headquartered in Québec, Canada.

The company’s shares closed last Wednesday at $2.90.